MicroRNAs (miRNAs) are small regulatory molecules post-transcriptionally suppressing
mRNA activity. Many miRNAs in various organisms have been cloned but many unknown …

Atrial fibrillation (AF) is a complex condition requiring holistic management with multiple
treatment decisions about optimal thromboprophylaxis, symptom control (and prevention of …

Atrial dysfunction has been widely considered a marker or consequence of other cardiac
conditions rather than the cause itself. Here, we propose the term atrial failure as a clinically …

While there is a clear clinical benefit of oral anticoagulation in patients with atrial fibrillation
(AF) and venous thromboembolism (VTE) in reducing the risks of thromboembolism, major …

Most patients with atrial fibrillation (AF) and risk factors for stroke require oral anticoagulation
(OAC) to decrease the risk of stroke or systemic embolism. This is now best achieved with …

Background: Several bleeding risk assessment models have been developed in atrial
fibrillation (AF) patients with oral anticoagulants, but the most appropriate tool for predicting …

Clinical practice in atrial fibrillation (AF) patient management is constantly evolving. In the
past 3 years, various new AF guidelines or focused updates have been published, given this …

Atrial fibrillation (AF) is the most common sustained arrhythmia in the population and is
associated with a significant clinical and economic burden. Rigorous assessment of the …

Thrombo-inflammation describes the complex interplay between blood coagulation and
inflammation that plays a critical role in cardiovascular diseases. The third Maastricht …

Objective: Patients with lower extremity peripheral artery disease (PAD) are at increased risk
of major adverse cardiovascular events. Numerous plasma biomarkers have been …